Oral Mucosa Absorption: How Buccal and Sublingual Work

By Jack Zheng, MS Pharmacy -- Founder of MIHIYO Labs

Summary

The oral mucosa can absorb active compounds quickly, but only when a small, permeable dose stays in contact with thin, highly vascular tissue long enough to cross it. In a controlled midazolam study, absolute bioavailability rose from 27.8% as a swallowed solution to 66.1% after 100 seconds of buccal contact, showing why retention matters as much as dosage form. Oral mucosa absorption therefore depends on anatomy, saliva, and molecule fit, not marketing language. For MIHIYO Labs, an oral dissolving strip (ODS) makes sense when low dose, fast onset, and partial first-pass bypass actually matter.

How does the oral mucosa absorb active compounds?

Oral mucosa absorption happens when a dissolved active crosses the lining of the mouth and enters the blood vessels underneath before it is swallowed. The route can work quickly because the tissue is accessible, vascular, and, for the absorbed fraction, partly avoids the gut and liver before reaching systemic circulation.¹²³

That does not mean the mouth is an open door. It is a selective barrier. Some molecules cross it well, some cross it poorly, and many do not cross it enough to justify a route-based claim.³⁴ In formulation terms, I treat the mouth as a limited fast lane, not a reservoir. If the dose is too large, too water-loving, too irritating, or too easy to swallow, the route advantage narrows fast.

Which parts of the mouth actually absorb best?

Not every part of the mouth behaves the same. The tissues under the tongue and in the floor of the mouth are thinner than the cheek, which is why sublingual delivery is usually discussed as the faster route. Review literature describes the buccal epithelium at roughly 500 to 800 micrometers thick, while the sublingual epithelium is much thinner at about 100 to 200 micrometers.¹² A thinner barrier gives a dissolved molecule less tissue to cross.

The buccal cheek still matters because it is robust, non-keratinized, and easier to hold a dosage form against for longer periods.²³ Harris and Robinson made the distinction clearly years ago: sublingual delivery is better suited to rapid absorption for some small permeants, while buccal delivery is less permeable but more practical for sustained contact systems.³ That is still the core engineering trade-off.

Under those epithelial layers sits the lamina propria and a dense vascular network. Hearnden and colleagues highlighted the oral mucosa's accessibility, blood supply, and partial bypass of hepatic first-pass metabolism as the main reason it remains attractive for both local and systemic delivery.⁵ Campisi and colleagues similarly noted that buccal blood vessels drain directly into the jugular system, which is why a fraction absorbed through the tissue can reach systemic blood without taking the full swallowed route first.²

What makes one dose cross the mucosa instead of getting swallowed?

Three things decide most of the outcome: molecule fit, contact time, and saliva.

First is molecule fit. Small, potent, reasonably lipophilic molecules usually have the best chance of crossing the oral mucosa in useful amounts.³⁴ Hydrophilic molecules, high molecular weight compounds, and bulky doses struggle more because they must pass through a stratified epithelial barrier that is designed to protect the body, not to welcome foreign material.³⁴

Second is contact time. A dissolved active has to stay against the tissue long enough to partition into it. Grass and colleagues showed this cleanly with microdosed midazolam: absolute bioavailability was 27.8% when the same dose was taken as a swallowed drinking solution, but 66.1% after 100 seconds of buccal exposure.⁶ The compound did not change. The contact window did.

Third is saliva. Saliva is necessary because it wets the dosage form and brings dissolved molecules to the tissue surface. But saliva also dilutes the dose, moves it away from the target site, and makes it easier to swallow early. Collins and Dawes measured the total surface area of the adult mouth at about 214.7 cm2 and estimated the salivary film covering oral surfaces at roughly 0.07 to 0.10 mm thick.⁷ That thin fluid layer is enough to help dissolution, but it also means the mouth is a moving, irrigated environment rather than a fixed chamber.

This is why oral mucosa absorption is not just about putting something "under the tongue." The geometry of the dose matters. A thin film, wafer, or patch can hold drug at one site. A pooled liquid or fast-swallowed powder usually cannot do that as consistently.¹³⁵

What do the numbers look like in real studies?

The easiest way to make the route practical is to compare the relevant tissue and kinetic differences side by side.

The table shows why I do not reduce this topic to "sublingual is better." Sublingual tissue is thinner and often faster, but it is also a harder place to control. Buccal tissue is thicker and less permeable, yet it can be easier to engineer around because a film can stay there longer.²³

The midazolam paper is the clearest proof that contact is not a side detail.⁶ If 100 seconds of controlled buccal exposure can more than double absolute bioavailability versus simple swallowing, then the question is not whether a dosage form dissolves in the mouth. The question is whether it creates useful tissue contact before the swallow reflex wins.

The melatonin crossover study makes the same point in a more supplement-adjacent context. In 14 healthy male volunteers, the immediate-release sublingual spray produced a much earlier and higher plasma peak than the oral prolonged-release tablet: Cmax 2332 +/- 950 pg/mL with Tmax 23.3 +/- 6.5 minutes versus Cmax 1151 +/- 565 pg/mL with Tmax 64.2 +/- 44.2 minutes.⁸ That does not prove that every strip will outperform every tablet. It shows that route and dosage form can change the kinetic profile when the molecule is route-sensitive.

What this means for MIHIYO products

For MIHIYO, oral mucosa absorption is a dosage-form discipline, not a headline claim. I am more interested in low-dose actives, short dissolve windows, and repeatable mucosal contact than in trying to stuff the mouth with large payloads. Every extra milligram makes film thickness, mouthfeel, and saliva washout harder to control. That is a formulation reality, not a branding preference.

This is why a route-led product like Mood-Boost needs to be thought through at the molecule level first. If the active combination is low dose and timing-sensitive, an oral dissolving strip can be a rational format. If the active is high dose or poorly permeable, the strip becomes mostly a convenience format and should be described that way. The route should earn its place pharmacologically.

I also keep a hard line between route science and product proof. The papers cited here are anatomy reviews, permeability reviews, and independent pharmacokinetic studies on model drugs or melatonin dosage forms.^1234568 They explain how oral mucosa absorption works. They do not directly prove the pharmacokinetics of a finished MIHIYO retail product, because we do not have a published human PK study on a MIHIYO strip itself.

For readers who want the next layer down, the route discussion connects directly to our articles on the first-pass effect in supplements, what bioavailability means on a label, and sublingual B12 absorption.

Where oral mucosa absorption falls short

The first limit is surface area. The whole mouth is not an absorptive field. Collins and Dawes showed that teeth and keratinized tissue occupy much of that 214.7 cm2 total surface area, leaving only part of the cavity as favorable non-keratinized tissue.⁷ In practice, the useful site is even smaller because the dose has to stay where you put it.

The second limit is permeability. Senel and Hincal were direct about this: membrane permeation is a limiting factor for many buccal drugs, which is why permeation enhancers keep being studied.⁴ The problem is that enhancer strategies come with their own trade-offs, including irritation, membrane damage, and toxicity risk if used badly.⁴ A route that depends on aggressive enhancement is already telling you the molecule is a difficult fit.

The third limit is swallow loss. Only the fraction absorbed through the tissue partly avoids first-pass metabolism. Everything swallowed becomes ordinary gastrointestinal exposure again.²³⁵ This is the reason I dislike exaggerated route claims. A strip, spray, or lozenge does not automatically bypass the gut. It creates an opportunity for partial transmucosal uptake. Whether that opportunity is captured depends on the molecule and the design.

The fourth limit is dosage size. The oral mucosa is best for potent, lower-dose actives. That is why emergency drugs and some fast-onset therapies fit the route better than gram-scale nutrition loads.¹⁵ Once the mass gets too high, the route usually becomes more about convenience than superior exposure.

The bottom line

Oral mucosa absorption works because thin, vascularized mouth tissue can take up part of a dissolved dose before it is swallowed.¹²⁵ The route is strongest when the active is low dose, permeable enough to cross, and held in contact with the tissue long enough to matter.³⁴⁶ The numbers make that practical: sublingual tissue is much thinner than buccal tissue, controlled buccal exposure can raise absolute bioavailability from 27.8% to 66.1%, and a sublingual melatonin spray can peak earlier and higher than a swallowed tablet.¹²⁶⁸ My formulation view is simple: oral mucosa absorption is real, but it is selective. If the molecule and the contact geometry do not fit the route, the route should not be oversold.

References

1. Hua S. Advances in Nanoparticulate Drug Delivery Approaches for Sublingual and Buccal Administration. Front Pharmacol. 2019. PMID: 31827435 / DOI: 10.3389/fphar.2019.01328. <https://pubmed.ncbi.nlm.nih.gov/31827435/>
2. Campisi G, Paderni C, Saccone R, Di Fede O, Wolff A, Giannola LI. Human buccal mucosa as an innovative site of drug delivery. Curr Pharm Des. 2010;16(6):641-652. PMID: 20388074 / DOI: 10.2174/138161210790883778. <https://pubmed.ncbi.nlm.nih.gov/20388074/>
3. Harris D, Robinson JR. Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci. 1992;81(1):1-10. PMID: 1619560 / DOI: 10.1002/jps.2600810102. <https://pubmed.ncbi.nlm.nih.gov/1619560/>
4. Senel S, Hincal AA. Drug permeation enhancement via buccal route: possibilities and limitations. J Control Release. 2001;72(1-3):133-144. PMID: 11389992 / DOI: 10.1016/S0168-3659(01)00269-3. <https://pubmed.ncbi.nlm.nih.gov/11389992/>
5. Hearnden V, Sankar V, Hull K, Juras DV, Greenberg M, Kerr AR, Lockhart PB, Patton LL, Porter S, Thornhill MH. New developments and opportunities in oral mucosal drug delivery for local and systemic disease. Adv Drug Deliv Rev. 2012;64(1):16-28. PMID: 21371513 / DOI: 10.1016/j.addr.2011.02.008. <https://pubmed.ncbi.nlm.nih.gov/21371513/>
6. Grass J, Rose P, Burhenne J, Blank A, Haefeli WE, Mikus G. Absolute Bioavailability of Microdosed Midazolam After Buccal Administration Is Dependent on Buccal Exposure Time. J Clin Pharmacol. 2021;61(4):550-556. PMID: 32976642 / DOI: 10.1002/jcph.1751. <https://pubmed.ncbi.nlm.nih.gov/32976642/>
7. Collins LM, Dawes C. The surface area of the adult human mouth and thickness of the salivary film covering the teeth and oral mucosa. J Dent Res. 1987;66(8):1300-1302. PMID: 3476596 / DOI: 10.1177/00220345870660080201. <https://pubmed.ncbi.nlm.nih.gov/3476596/>
8. Ait Abdellah S, Raverot V, Gal C, Guinobert I, Bardot V, Blondeau C, Claustrat B. Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers. Drugs R D. 2023;23(3):219-229. PMID: 37438493 / DOI: 10.1007/s40268-023-00431-9. <https://pubmed.ncbi.nlm.nih.gov/37438493/>

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs. Focused on the R&D of high-bioavailability, fast-absorption oral dissolving strips.